<?xml version="1.0" encoding="UTF-8"?>
<p>Cholinesterase inhibitors, such as rivastigmine, have been proved beneficial to the improvement of global cognition and clinical manifestations as well as neuropsychiatric testing (especially for attention and executive functioning amelioration) by several large-scale multicenter randomized placebo-controlled trials [
 <xref rid="B95" ref-type="bibr">95</xref>â€“
 <xref rid="B98" ref-type="bibr">98</xref>]. However, Donepezil, also a cholinesterase inhibitor, was not effective for global cognitive improvement or other neuropsychiatric symptoms in PD-MCI or PDD in a large randomized controlled study [
 <xref rid="B99" ref-type="bibr">99</xref>, 
 <xref rid="B100" ref-type="bibr">100</xref>], although its beneficial effect was reported in some small placebo-controlled studies [
 <xref rid="B99" ref-type="bibr">99</xref>].
</p>
